Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 21764
                    [Title] => Boehringer Ingelheim tops survey
                    [Summary] => 
            
                    [DatePublished] => 2007-10-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 158159
                    [Title] => Anti-AIDS drugs now affordable for Pinoys
                    [Summary] => The Acquired Immune-Deficiency Syndrome (AIDS) remains a modern scourge that seems to have equaled the devastating effect of the bubonic plague during the Middle Ages. The deadly disease has taken its devastating toll mainly in the developing nations of Sub-Saharan Africa and Asia.


In the Philippines, Boehringer Ingelheim Phils. (BIPHI) realizes that making anti-HIV/AIDS drugs more accessible and affordable to afflicted patients is critical to successfully combating the AIDS dilemma.


                    [DatePublished] => 2002-04-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 143141
                    [Title] => Boehringer Ingelheim, 35: Making a difference in the lives of Pinoys
                    [Summary] => Boehringer Ingelheim Phils. Inc. (BIPHI), one of the country’s leading pharmaceutical companies, celebrated last Friday its 35th anniversary of making a difference in the lives of Filipinos. 


Its mother company, Boehringer Ingelheim, began operating some 116 years ago.


BIPHI is one of the top 10 pharmaceutical companies in the country. Its unwavering commitment is to develop truly innovative drugs for the treatment of various diseases like hypertension, chronic obstructive pulmonary disease (COPD) and osteoarthritis.


                    [DatePublished] => 2001-12-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 83568
                    [Title] => Benefits of inhaled therapy for COPD cited
                    [Summary] => SAN FRANCISCO – Data from 13 scientific presentations of Boehringer Ingelheim’s tiotropium, the first once-daily inhaled therapy being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), were presented at the 97th International Conference of the American Thoracic Society.


COPD is the world’s fourth leading cause of death with approximately three million people dying each year from the smoking-related respiratory illness.


                    [DatePublished] => 2001-06-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Real Estate
                    [SectionUrl] => real-estate
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 83550
                    [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
                    [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.


The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.


                    [DatePublished] => 2001-06-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

INGELHEIM

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 21764
                    [Title] => Boehringer Ingelheim tops survey
                    [Summary] => 
            
                    [DatePublished] => 2007-10-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 158159
                    [Title] => Anti-AIDS drugs now affordable for Pinoys
                    [Summary] => The Acquired Immune-Deficiency Syndrome (AIDS) remains a modern scourge that seems to have equaled the devastating effect of the bubonic plague during the Middle Ages. The deadly disease has taken its devastating toll mainly in the developing nations of Sub-Saharan Africa and Asia.


In the Philippines, Boehringer Ingelheim Phils. (BIPHI) realizes that making anti-HIV/AIDS drugs more accessible and affordable to afflicted patients is critical to successfully combating the AIDS dilemma.


                    [DatePublished] => 2002-04-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 143141
                    [Title] => Boehringer Ingelheim, 35: Making a difference in the lives of Pinoys
                    [Summary] => Boehringer Ingelheim Phils. Inc. (BIPHI), one of the country’s leading pharmaceutical companies, celebrated last Friday its 35th anniversary of making a difference in the lives of Filipinos. 


Its mother company, Boehringer Ingelheim, began operating some 116 years ago.


BIPHI is one of the top 10 pharmaceutical companies in the country. Its unwavering commitment is to develop truly innovative drugs for the treatment of various diseases like hypertension, chronic obstructive pulmonary disease (COPD) and osteoarthritis.


                    [DatePublished] => 2001-12-10 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 83568
                    [Title] => Benefits of inhaled therapy for COPD cited
                    [Summary] => SAN FRANCISCO – Data from 13 scientific presentations of Boehringer Ingelheim’s tiotropium, the first once-daily inhaled therapy being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD), were presented at the 97th International Conference of the American Thoracic Society.


COPD is the world’s fourth leading cause of death with approximately three million people dying each year from the smoking-related respiratory illness.


                    [DatePublished] => 2001-06-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Real Estate
                    [SectionUrl] => real-estate
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 83550
                    [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
                    [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.


The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.


                    [DatePublished] => 2001-06-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Boehringer Ingelheim tops survey

October 18, 2007 - 12:00am

Science and Environment

Anti-AIDS drugs now affordable for Pinoys

April 22, 2002 - 12:00am

The Acquired Immune-Deficiency Syndrome (AIDS) remains a modern scourge that seems to have equaled the devastating effect of the bubonic plague during the Middle Ages. The deadly disease has taken its devastating...

Science and Environment

Boehringer Ingelheim, 35: Making a difference in the lives of Pinoys

December 10, 2001 - 12:00am

Boehringer Ingelheim Phils. Inc. (BIPHI), one of the country’s leading pharmaceutical companies, celebrated last Friday its 35th anniversary of making a difference in the lives of Filipinos. Its mother company,...

Science and Environment

Benefits of inhaled therapy for COPD cited

June 25, 2001 - 12:00am

SAN FRANCISCO – Data from 13 scientific presentations of Boehringer Ingelheim’s tiotropium, the first once-daily...

Real Estate

Boehringer Ingelheim sets largest cardiovascular protection trial

June 18, 2001 - 12:00am

MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors. The study, announced...

Science and Environment